Cosmo Pharmaceuticals N.V. (0RGI.L)
CHF 59.0
(-1.5%)
CHF 59.0
(-1.5%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.83 Million EUR | -98.94% |
| 2022 | 173.59 Million EUR | 2.17% |
| 2021 | 169.91 Million EUR | 1.05% |
| 2020 | 168.14 Million EUR | 2.01% |
| 2019 | 164.83 Million EUR | 4.23% |
| 2018 | 158.15 Million EUR | 3433.29% |
| 2017 | 4.47 Million EUR | -15.69% |
| 2016 | 5.3 Million EUR | -34.72% |
| 2015 | 8.13 Million EUR | -25.59% |
| 2014 | 10.93 Million EUR | -6.96% |
| 2013 | 11.74 Million EUR | -8.48% |
| 2012 | 12.83 Million EUR | 489.94% |
| 2011 | 2.17 Million EUR | -37.78% |
| 2010 | 3.49 Million EUR | 17.51% |
| 2009 | 2.97 Million EUR | -30.69% |
| 2008 | 4.29 Million EUR | 178.83% |
| 2007 | 1.54 Million EUR | -82.29% |
| 2006 | 8.69 Million EUR | -59.67% |
| 2005 | 21.55 Million EUR | 11.46% |
| 2004 | 19.34 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 851 Thousand EUR | -53.72% |
| 2024 Q2 | 1.45 Million EUR | 70.98% |
| 2023 Q4 | 1.83 Million EUR | 70.44% |
| 2023 Q1 | 174.76 Million EUR | 0.67% |
| 2023 Q2 | 175.54 Million EUR | 0.45% |
| 2023 FY | 1.83 Million EUR | -98.94% |
| 2023 Q3 | 1.07 Million EUR | -99.39% |
| 2022 FY | 173.59 Million EUR | 2.17% |
| 2022 Q4 | 173.59 Million EUR | 0.44% |
| 2022 Q2 | 171.82 Million EUR | 0.46% |
| 2022 Q1 | 171.04 Million EUR | 0.66% |
| 2022 Q3 | 172.84 Million EUR | 0.59% |
| 2021 Q2 | 168.11 Million EUR | 0.64% |
| 2021 FY | 169.91 Million EUR | 1.05% |
| 2021 Q3 | 169.16 Million EUR | 0.62% |
| 2021 Q1 | 167.04 Million EUR | -0.66% |
| 2021 Q4 | 169.91 Million EUR | 0.45% |
| 2020 Q4 | 168.14 Million EUR | 1.7% |
| 2020 Q2 | 168.01 Million EUR | 1.74% |
| 2020 FY | 168.14 Million EUR | 2.01% |
| 2020 Q1 | 165.13 Million EUR | 0.18% |
| 2020 Q3 | 165.33 Million EUR | -1.6% |
| 2019 Q3 | 163.46 Million EUR | -0.13% |
| 2019 Q1 | 162.24 Million EUR | 2.59% |
| 2019 Q2 | 163.67 Million EUR | 0.88% |
| 2019 FY | 164.83 Million EUR | 4.23% |
| 2019 Q4 | 164.83 Million EUR | 0.84% |
| 2018 Q1 | 3.87 Million EUR | -13.47% |
| 2018 FY | 158.15 Million EUR | 3433.29% |
| 2018 Q4 | 158.15 Million EUR | 0.25% |
| 2018 Q3 | 157.75 Million EUR | 3599.58% |
| 2018 Q2 | 4.26 Million EUR | 10.1% |
| 2017 Q4 | 4.47 Million EUR | 9.98% |
| 2017 FY | 4.47 Million EUR | -15.69% |
| 2017 Q1 | 4.36 Million EUR | -17.78% |
| 2017 Q2 | 4.93 Million EUR | 12.97% |
| 2017 Q3 | 4.07 Million EUR | -17.46% |
| 2016 Q2 | 7.41 Million EUR | 24.87% |
| 2016 FY | 5.3 Million EUR | -34.72% |
| 2016 Q1 | 5.93 Million EUR | -26.96% |
| 2016 Q3 | 4.57 Million EUR | -38.33% |
| 2016 Q4 | 5.3 Million EUR | 16.07% |
| 2015 Q4 | 8.13 Million EUR | 21.62% |
| 2015 Q3 | 6.68 Million EUR | -32.88% |
| 2015 FY | 8.13 Million EUR | -25.59% |
| 2015 Q2 | 9.96 Million EUR | 16.57% |
| 2015 Q1 | 8.54 Million EUR | -21.8% |
| 2014 Q4 | 10.93 Million EUR | 14.56% |
| 2014 Q2 | 10.81 Million EUR | 14.37% |
| 2014 Q1 | 9.45 Million EUR | -19.5% |
| 2014 FY | 10.93 Million EUR | -6.96% |
| 2014 Q3 | 9.54 Million EUR | -11.79% |
| 2013 Q1 | 11.35 Million EUR | -11.58% |
| 2013 FY | 11.74 Million EUR | -8.48% |
| 2013 Q4 | 11.74 Million EUR | 12.79% |
| 2013 Q3 | 10.41 Million EUR | -17.68% |
| 2013 Q2 | 12.65 Million EUR | 11.48% |
| 2012 Q4 | 12.83 Million EUR | 0.0% |
| 2012 FY | 12.83 Million EUR | 489.94% |
| 2012 Q2 | 1.77 Million EUR | 0.0% |
| 2012 Q3 | - EUR | -100.0% |
| 2011 Q2 | 2.73 Million EUR | 0.0% |
| 2011 Q4 | 2.17 Million EUR | 0.0% |
| 2011 FY | 2.17 Million EUR | -37.78% |
| 2010 Q2 | 4.46 Million EUR | 0.0% |
| 2010 Q4 | 3.49 Million EUR | 0.0% |
| 2010 FY | 3.49 Million EUR | 17.51% |
| 2009 Q4 | 2.97 Million EUR | 0.0% |
| 2009 FY | 2.97 Million EUR | -30.69% |
| 2008 FY | 4.29 Million EUR | 178.83% |
| 2007 FY | 1.54 Million EUR | -82.29% |
| 2006 FY | 8.69 Million EUR | -59.67% |
| 2005 FY | 21.55 Million EUR | 11.46% |
| 2004 FY | 19.34 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Relief Therapeutics Holding AG | 4.31 Million CHF | 57.342% |
| Tecan Group AG | 316.09 Million CHF | 99.418% |
| Santhera Pharmaceuticals Holding AG | 25.06 Million CHF | 92.662% |
| Basilea Pharmaceutica AG | 128.6 Million CHF | 98.57% |
| Bachem Holding AG | 401 Thousand CHF | -358.603% |
| Siegfried Holding AG | 525 Million CHF | 99.65% |
| Molecular Partners AG | 3.65 Million CHF | 49.644% |